Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.86 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL8818249 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL7713436 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL209886 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL10478288 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL2794537 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL2705733 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL3417348 | 1.00 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL4494449 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL14720249 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL2794532 | 0.97 | SLC22A1 (0.80) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120172821-B | Alkynol compound, preparation thereof and application thereof in addition type liquid silicone rubber | 广东盛唐新材料技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260092239-A1 | CLEANING COMPOSITION | DONGWOO FINE CHEM CO LTD (KR) | 2026-04-02 | — | — | US | claimed |
| CN-116425760-B | Synthesis method of chiral (-) -cephalotaxine, intermediate and analogue thereof | 兰州大学 | 2024-11-26 | — | — | CN | claimed |
| US-11858885-B2 | Cellulosic complex and applications thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-01-02 | — | — | US | claimed |
| CN-116425760-A | Synthesis method of chiral (-) -cephalotaxine, intermediate and analogue thereof | 兰州大学 | 2023-07-14 | — | — | CN | claimed |
| US-20220185810-A1 | Novel Process for the Preparation of Filgotinib and Intermediates Thereof | UNICHEM LABORATORIES LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| US-20220153669-A1 | CELLULOSIC COMPLEX AND APPLICATIONS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-05-19 | — | — | US | claimed |
| CN-111978240-B | Preparation method of 4,4' -oxo-bis-phthalimide | 南京康德祥医药科技有限公司 | 2022-03-11 | — | — | CN | claimed |
| EP-3947381-A2 | NOVEL PROCESS FOR THE PREPARATION OF FILGOTINIB AND INTERMEDIATES THEREOF | Unichem Laboratories Ltd (IN) | 2022-02-09 | — | — | EP | claimed |
| CN-113677676-A | Novel method for preparing non-gautinib and intermediate thereof | 联合化学实验室有限公司 | 2021-11-19 | — | — | CN | claimed |
| CN-102421742-A | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC | 2012-04-18 | — | — | CN | claimed |
| EP-2427417-A1 | SALTS OF 3-PENTYLPHENYLACETIC ACID AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | claimed |
| WO-2010127448-A1 | SALTS OF 3-PENTYLPHENYLACETIC ACID AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | claimed |
| US-7622595-B2 | chemical intermediates to insecticides and anticoagulant inhibitors of factor Xa having a 1-halophenyl-3-trifluoromethylpyrazole moeity; 1-(1-chloro-2-phenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-24 | — | — | US | claimed |
| US-7473788-B2 | Analogs of terpene trilactones from Ginkgo biloba and related compounds and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-01-06 | — | — | US | claimed |
| US-20070098632-A1 | Analogs of terpene trilactones from ginkgo biloba and related compounds and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-05-03 | — | — | US | claimed |
| US-7145021-B2 | Analogs of terpene trilactones from Ginkgo biloba and related compounds and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-12-05 | — | — | US | claimed |
| US-20030225052-A1 | Analogs of terpene trilactones from Ginkgo biloba and related compounds and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2003-12-04 | — | — | US | claimed |
| US-6652665-B1 | Immersing and aggitating in preheated solution containing quaternary ammonium fluoride and hydrophobic nonhydroxylic aprotic solvent | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2003-11-25 | — | — | US | claimed |
| WO-2003082185-A2 | ANALOGS OF TERPENE TRILACTONES FROM GINKGO BILOBA AND RELATED COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2003-10-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070098632-A1 | Analogs of terpene trilactones from ginkgo biloba and related compounds and uses thereof | GRK5, GPR55, GPBAR1 | SLC22A1 4580/4885SLC22A2 4635/4885ALDH1A1 2107/4885 |
| US-20260092239-A1 | CLEANING COMPOSITION | SETDB1, SETD7, ITGB2 | SLC22A1 2900/4885SLC22A2 3032/4885ALDH1A1 883/4885 |
| US-20030225052-A1 | Analogs of terpene trilactones from Ginkgo biloba and related compounds and uses thereof | GPBAR1, GRK5, CNR1 | SLC22A1 4612/4885SLC22A2 4658/4885ALDH1A1 1337/4885 |
| US-20220153669-A1 | CELLULOSIC COMPLEX AND APPLICATIONS THEREOF | CEL, DBF4, NAF1 | SLC22A1 3055/4885SLC22A2 2897/4885ALDH1A1 4633/4885 |
| US-11858885-B2 | Cellulosic complex and applications thereof | CEL, DBF4, NAF1 | SLC22A1 3055/4885SLC22A2 2897/4885ALDH1A1 4633/4885 |
| US-20220185810-A1 | Novel Process for the Preparation of Filgotinib and Intermediates Thereof | ABL1, JAK1, JAK3 | SLC22A1 4630/4885SLC22A2 4640/4885ALDH1A1 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.